Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft

Experimental Hematology

Volumn 28, Issue 1, 2000, Pages 104-111

  Corsetti, Maria Teresa ^a   Lerma, Enrica ^a   Dejana, Anna ^a   Cavaliere, Marina ^a   Figari, Osvaldo ^a   Vassallo, Franca ^a   Abate, Monica ^a   Luchetti, Silvia ^a   Piaggio, Giovanna ^a   Parodi, Cristina ^a   Pira, Giuseppina Li ^b   Manca, Fabrizio ^b   Carella, Angelo Michele ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b ADVANCED BIOTECHNOLOGY CENTER   (Italy)

Author keywords

Autologous stem cell transplant; Chronic myelogenous leukemia; Peripheral blood progenitor cells; Quantitative competitive RT PCR

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYTARABINE; ETOPOSIDE; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; AUTOGRAFT; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BONE MARROW PURGING; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0033977635     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00135-6     Document Type: Article

References (30)

1. Carella A., Podesta M., Frassoni F., Raffo M., Pollicardo N., Pungolino E., Vimercati R., Sessarego M., Parodi C., Rabitti C., Ferrero R., Benvenuto F., Figari O., Carlier P., Levcasis G., Valbonesi M., Vitale V., Giordano D., Pierluigi D., Nati S., Guerracio A., Rosso C., Saglio G. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant. 12:1993;267.
2. Chalmers E., Franklin I., Kelsey S., Newland A., Clark R., Sproul A., Crotty G., McCann S., Fielding A., Goldstone A., Hepplestone A., Watson W., Sharp R., Tansey P. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine. mobilization of Philadelphia-negative peripheral blood stem cells Br J Haematol. 96:1997;627.
3. Heinzinger M., Waller C., Rosenstiel A., Scheid S., Burger K., Lange W. Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. Leukemia. 12:1998;333.
4. Fischer T., Neubauer A., Mohm J., Huhn D., Busemann C., Link H., Arseniev L., Bussing B., Novotny J., Ganser A., Duyster J., Bunjes D., Kreiter S., Aulitzky W., Hehlmann R., Huber C. Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML. Bone Marrow Transplant. 21:1998;1029.
5. Verfaillie C.M., Bhatia R., Steinbuch M., DeFor T., Hirsch B., Miller J.S., Weisdorf D., McGlave P.B. Comparative analysis of autografting in chronic myelogenous leukemia. effects of priming regimen and marrow or blood origin of stem cells Blood. 92:1998;1820.
6. McGlave P.H., DeFabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J., Simonsson B., Carella A.M., Aeppli D. Autologous transplant for chronic myelogenous leukemia. results from eight transplant groups Lancet. 343:1994;1486.
7. Carella A., Cunningham I., Lerma E., Dejana A., Benvenuto F., Podestá M., Celesti L., Chimirri F., Abate M., Vassallo F., Figari O., Parodi C., Sessarego M., Valbonesi M., Carlier P., Prencipe E., Gatti A., Van Den Berg D., Hoffman R., Frassoni F. Mobilization and transplantation of Philadelpia-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol. 15:1997;1575.
8. Carella A., Lerma E., Corsetti M.T., Dejana A., Celesti L., Vassallo F., Abate M., Soracco M., Benvenuto F., Figari O., Podestá M., Piaggio G., Sessarego M., Parodi C., Rubagotti A. Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood. 93:1999;1534.
9. Talpaz M., Kantarjian H., Liang J., Calvert L., Hamer J., Tibbits P., Durett A., Claxton D., Giralt S., Khouri I., Przepiorka D., Van Besien K., Andersson B., Mehra R., Gajewski J., Seong D., Hester J., Estey E., Korbling M., Pollicardo N., Berenson R., Heimfeld S., Champlin Deisseroth A.B. Percentage of philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on the percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 85:1995;3257.
10. Corsetti M.T., Podesta M., Lerma E., Li Pira G., Manca F., Carella A.M. Peripheral blood progenitor cells mobilized early at diagnosis in patients with chronic myelogenous leukemia contain very low amounts of BCR-ABL transcripts. Leukemia. 12:1998;998.
11. Corsetti M.T., Lerma E., Dejana A., Basta P., Ferrara R., Benvenuto F., Vassallo F., Abate M., Piaggio G., Parodi C., Sessarego M., Li Pira G., Manca F., Carella A.M. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia. Leukemia. 13:1999;999.
12. Lion T., Gaiger A., Henn T., Horth E., Haas O., Geissler K., Gadner H. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia. 9:1995;1353.
13. Hochhaus A., Lin F., Reiter A., Skladny H., Mason P., van Rhee F., Shepherd P., Allan N., Hehlmann R., Goldman J., Cross N. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood. 87:1996;1549.
14. Lion T., Henn T., Gaiger A., Kalhs P., Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet. 341:1993;275.
15. Cross N, Feng L, Chase A, Bungey J, Hughes T, Goldman J (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929.
16. Carella AM, Lerma E, Celesti L, Dejana A, Panagiotis Z, Corsetti MT, Frassoni F (1998) Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen, Br J Haematol 100:445.
17. Nagler A., Ackerstein A., Barak V., Slavin S. Treatment of chronic myelogenous leukemia with Il-2 and interferon-α J Hematotherapy. 11:1994;75.
18. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156.
19. Saglio G., Pane F., Gottard iE Frigeri F., Buonaiuto M., Guerrasio A., de Micheli D., Parziale A., Fornaci M., Martinelli G., Salvatore F. Consistent amount of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood. 87:1996;1075.
20. Melo J. The molecular biology of chronic myeloid leukaemia. Leukemia. 10:1996;751.
21. Talpaz M., Kantarjian H.M., O'Brien S., Kurzrock R. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. Baillieres Clin Haematol. 10:1997;291.
22. Anonymous Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 92:1998;1541.
23. Ohnishi K., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., Dohy H., Mizoguchi H., Miyawaki S., Tsubaki K., Miura Y., Omine M., Kobayashi T., Naoe T., Ohshima T., Hirashima K., Ohtake S., Takahashi I., Morishima Y., Naito K., Asou N., Tanimoto M., Sakuma A., Ohno R. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk Res. 22:1998;779.
24. Thaler J., Hilbe W., Apfelbeck U., Linkesch W., Sill H., Seewann H., Pont J., Bernhart M., Stoger M., Niessner H., Abbrederis K., Geissler D., Hausmaninger H., Lin W., Ludwig H., Lang A., Duba C., Fluckinger T., Greil R., Grunewald K., Konwalinka G., Niederwieser D., Fridrik M. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML. results of the Austrian multi-center phase II study Leuk Res. 21:1997;75.
25. Shepherd P.C., Richards S.M., Allan N.C. Progress with interferon in CML - results of the MRC UK CML III study. Bone Marrow Transplant. 17:1996;3-S15. Suppl.
26. Ozer H., George S., Schiffer C., Rao K., Rao P., Wuster-Hill D., Arther D., Powell B., Gottlieb A., Peterson B., Rai K., Testa J., LeBeau M., Tantravahi R., Bloomfield C. Prolonged subcutaneous administration of recombinant alfa-2b interferon in patients with previously untreated Philadelphia-chromosome positive chronic-phase chronic myelogenous leukemia. effect on remission duration and survival: Cancer and Leukemia Group B Study 8583 Blood. 82:1993;2975.
27. Allan N., Richards S., Shepard P. UK Medical Research Council randomized multicenter trial on interferon-a in chronic myelogenous leukemia-improved survival irrespective of cytogenetic response. Lancet. 345:1995;1392.
28. Helman R., Group G.C.S. Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 84:1994;4064.
29. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myelogenous leukemia. N Engl J Med. 330:1994;820.
30. Carella A.M., Frassoni F., Melo J., Sawyers C., Eaves C., Eaves A., Apperley J., Tura S., Hehlmann R., Reiffers J., Lerma E., Goldman J. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 82:1997;478.